Our Team in the News

BioPlan Associates' Ronald Rader

Ron Rader, Sr. Dir. Technical Research: named Editor-in-Chief of Biopharmaceuticals a new peer-reviewed journal from Landes Bioscience. Biopharmaceuticals is the first and only peer-reviewed journal about biopharmaceuticals. Biopharmaceuticals seeks submission of articles concerning biopharmaceuticals and the industry. Please contact the Editor-in-Chief if interested in submitting an article.

BioPlan Associates' Faiz Kermani PhD

Dr Faiz Kermani, Advisory Board: Has helped establish the "Global Health Education Foundation" (GHEF), a not-for-profit healthcare charity to improve educational resources and training for healthcare professionals in developing countries.
At least 1.3 billion people worldwide lack access to the most basic healthcare. The new non-profit foundation, Global Health Education Foundation, aims to tackle such issues. As President of GHEF, Dr Kermani is supporting the R&D focus of the charity to reduce health disparities among developing countries. In particular, the lack of appropriate educational resources and training opportunities for healthcare professionals. http://www.globalhef.org

BioPlan Associates' Managing Director Eric Langer

Eric Langer, Managing Partner: On Advisory Board of “BioProcess Asia Pacific Conference” July 2010 Singapore.
The Biopharmaceutical market in Asia pacific is growing at a rate among the highest in the globe. This is creating a strong need for production of biopharmaceuticals at higher qualities and volumes. Bioprocess AsiaPacific brings together global leaders within biopharmaceutical industry to explore dynamic strategies, benchmark technologies and analyze sustaining the growth of the industry. http://fleminggulf.com/conference/life-science/BioProcessAsiaPacific.

Publications, Reports and Books

Quick Guide to healthcare and Biotechnology in the Middle East


Until recently, the Middle East has accounted for a fraction of global pharmaceutical sales, but BioPlan’s newly released A Quick Guide™ to Healthcare and Biotechnology in the Middle East shows that dramatic change is underway. The Middle East has been low on the agenda of the pharmaceutical industry, due to reliance on strong growth in the US, European and Japanese markets, but the slowdown and cost containment pressures in these markets have persuaded the pharmaceutical industry to cast its eyes further afield.

The total Middle East regional value is around US$10.6 billion and growing rapidly. Multinational pharmaceutical companies can no longer ignore the region’s huge potential. Due to varying socio-economic conditions and political developments across the Middle East, it is entirely conceivable for companies to find opportunities for products in almost every therapeutic area.

The high demand for premium products has led to multinational companies having dominated the Middle East. Pharmaceutical companies still need to be aware of the region’s dynamics. This is still very much an emerging market and you have to do your homework.

Strong Healthcare Industry Investments

With most headline coverage limited to the region’s politics, the dramatic changes in Middle Eastern healthcare have almost gone unnoticed. However, rising demand for healthcare is transforming this part of the world. As a result there are new opportunities for private companies that did not exist even a few years ago. Many countries in the region will face 2% annual increases in healthcare expenditure needs as a result of the aging of their populations.

The book highlights the difficulties that governments have had in planning for future demand has led to openings for private sector involvement in healthcare and this has been characterized by a number of high profile, innovative initiatives. In Oman, up to US$1 billion is being invested to build an integrated health care city outside the capital, Muscat. In the United Arab Emirates, a similar project is underway, valued at US$3.4 billion. Furthermore, the government actually handed over ownership of three public hospitals to a private company. In Bahrain, construction of a US$1.6 billion health island, known as Dilmunia, has begun. Dilmunia will feature a mix of residential, leisure and commercial facilities encompassing comprehensive health environment.

Biotech Transforming Middle Eastern Healthcare

Companies with an interest in biotech are finding that the Middle East offers them a wealth of attractive opportunities. Due to the changing disease profile, there is a growing demand in the Middle East for biotech products and this is reflected by the decisions of multinational companies to invest in the region. Like patients elsewhere in the world, it should come as no surprise that those in the Middle East are eager to gain access to the latest and innovative new medicines.

Aside from specialized biotech companies such as Amgen and Genzyme, many of the major pharmaceutical companies including Roche, Novartis, Pfizer and GlaxoSmithKline market biotech products in the Middle East. NovoNordisk, which has a specialty in diabetes, has performed very strongly in the region due to the rise in the disease. Smaller biotech companies have also targeted the Middle East for growth. Generex Biotech has been using local consultants to aggressively source and evaluate prospective licensing opportunities for its products.

The success of foreign companies with biotech products has not gone unnoticed by regional pharmaceutical companies and a number have set up dedicated R&D divisions to develop biotech products. Many governments wish to promote the development of a mainstream biotech industry and have created incentives to kick-start the sector. Since biotech drugs are expensive, they believe that opting for local generated biotech products will prove cost effective.

Going forward, one of the most impressive developments is DuBiotech in the UAE, which is the world’s first free-zone dedicated to the life science industry. It has been seeking to attract a range of companies, ranging from small start-ups through to more established international companies. Among the R&D programs being encouraged at DuBiotech, stem cell research will be permitted in line with international regulations.

Edited by Dr. Faiz Kermani.
Published by BioPlan Associates, Inc. April 2009
ISBN 978-1-934106-15-0

Order Now

  • Middle East market is characterized by a rising demand for the latest medicines:
    • Estimated population of 280 million, one of the fastest growing in the world
    • Countries face 2% annual increases in healthcare expenditure
    • Increase in both communicable and non-communicable diseases
  • Middle East market accounts for less than 2% of global pharmaceutical sales but is growing fast:
    • BioPlan values the current total ME pharmaceutical market at around US$10.6 billion
    • Market will exceed US$15 billion by 2014
    • Egypt is the largest market, closely followed by Israel, Iran and Saudi Arabia
  • Major growth in the Middle Eastern market will occur in the Gulf Cooperation Council (GCC) countries:
    • In 2008, the GCC market was worth close to US$4 billion
    • Strong demand for branded products, which reach these markets via imports
    • The Saudi Arabian pharmaceutical market could reach US$2 billion in value by 2012
  • The Israeli pharmaceutical market is growing at 9% per year and could be worth US$2.45 billion by 2012:
    • Pharmaceuticals account for between 15% and 20% of total health expenditure
  • International pharmaceutical and biotech companies recognize the region’s potential and are moving in:
    • Pfizer, Amgen, AstraZeneca, Genzyme, Pfizer and Wyeth
    • GSK exceeded 10% marketshare in Saudi Arabia
    • Indian companies have been attempting to penetrate the region due to a strong demand for generics
  • Leading domestic manufacturers are developing innovative R&D alongside their generics businesses:
    • Israel’s Teva generates most of its revenue outside its home market
    • Jordan’s Hikma is now the fifth largest pharmaceutical manufacturer in the Middle East and North Africa region
    • UAE’s Julphar recently announced a US$1.23 billion investment plan for 2008-2011